PDCD11: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: PDCD11

NCBI ID: G22984

PDCD11

PDCD11: A Potential Drug Target Or Biomarker for Various Diseases

PDCD11 (Apoptosis-linked gene 4) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and its association with the apoptosis process make it an attractive target for researchers to explore.

PDCD11 is a member of the PDCD gene family, which is known for its role in the regulation of apoptosis, or programmed cell death. The PDCD gene family is composed of four genes: PDCD1, PDCD2, PDCD3, and PDCD4. These genes are located on chromosome 17q11 and encode for proteins that are involved in the regulation of cell survival and death.

PDCD11 is a non-coding RNA gene that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is primarily expressed in the brain and has been shown to be involved in the regulation of apoptosis.

The apoptosis process is a natural mechanism that helps cells eliminate themselves when they are no longer needed or when damage has occurred. It is a critical process that helps maintain homeostasis and remove damaged or dysfunctional cells. However, when the apoptosis process is imrupted or goes awry, it can lead to the development of diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

PDCD11 has been shown to be involved in the regulation of apoptosis in various tissues and organs. For example, studies have shown that PDCD11 is expressed in the brains of mice and that it is involved in the regulation of apoptosis. Additionally, PDCD11 has been shown to be involved in the regulation of apoptosis in human tissues, including the brain and the liver.

PDCD11 has also been shown to be a potential drug target or biomarker for the treatment of various diseases. For example, studies have shown that inhibiting PDCD11 can protect against neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, PDCD11 has been shown to be involved in the regulation of cancer cell survival, which makes it an attractive target for cancer treatments.

In addition to its potential as a drug target or biomarker, PDCD11 is also a promising candidate for use as a diagnostic tool. Studies have shown that PDCD11 can be used as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive candidate for use in clinical trials as a diagnostic tool.

In conclusion, PDCD11 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. Its involvement in the regulation of apoptosis and its association with the development of diseases such as cancer, neurodegenerative diseases, and autoimmune disorders make it an attractive target for researchers to explore. Further studies are needed to fully understand the role of PDCD11 in the regulation of apoptosis and its potential as a drug target or biomarker.

Protein Name: Programmed Cell Death 11

Functions: Essential for the generation of mature 18S rRNA, specifically necessary for cleavages at sites A0, 1 and 2 of the 47S precursor. Directly interacts with U3 snoRNA

The "PDCD11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDCD11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets